Clinical Trial Update: TIL Therapy for Metastatic Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tumor-infiltrating lymphocyte therapy for metastatic renal cell carcinoma has completed; results were posted on 2024-11-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Tumor-infiltrating lymphocyte (TIL) therapy

Snippet

Sponsor: Inge Marie Svane | Conditions: Metastatic Renal Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2024-11-22